Exchange: NASDAQ·Updated 06:17 PM EDT
News
all
press releases
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -87.81% and +4.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
Key PointsThe executive disposed of 3,313 shares on July 2, 2026, for a total transaction value of about $285,000...
Nasdaq News: Markets
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Key PointsAn ANI Pharmaceuticals executive reported selling 2,850 shares directly for about $240,000 on June 29, 2026...
Nasdaq News: Markets
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
Zacks
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
Zacks
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
ANIP bets on Cortrophin Gel to power 2026 growth as rare disease sales become the majority of revenues. What must keep working?
Zacks

Advertisement|Remove ads.